ASPiRATION: Australian observational cohort study of comprehensive genomic profiling in metastatic lung cancer tissue.
Antony J MersiadesBenjamin J SolomonChee Khoon LeeMichelle M CumminsLucille SebastianMandy L BallingerEmily CollignonOlivia Mh TurnbullSonia YipRachael Lisa MortonChris BrownPatrick J WheelerMalinda ItchinsR John SimesNick PavlakisPublished in: Future oncology (London, England) (2023)
ASPiRATION is a national prospective observational cohort study assessing the feasibility, clinical and economic value of up-front tissue-based comprehensive genomic profiling (CGP) to identify actionable genomic alterations in participants with newly diagnosed metastatic non-squamous non-small-cell lung cancer in Australia. This study will enrol 1000 participants with tumor available for CGP and standard of care molecular testing ( EGFR / ALK/ROS1 ). Participants with actionable variants may receive novel targeted treatments through ASPiRATION-specific substudies, other trials/programs. Clinical outcome data will be collected for a minimum of 2 years. Study outcomes are descriptive, including the ability of CGP to identify additional actionable variants, leading to personalized treatment recommendations, and will describe the feasibility, efficiency, cost and utility of implementation of CGP nationally.
Keyphrases
- copy number
- small cell lung cancer
- squamous cell carcinoma
- quality improvement
- healthcare
- ultrasound guided
- single cell
- public health
- primary care
- type diabetes
- high grade
- dna damage
- clinical practice
- low grade
- metabolic syndrome
- gene expression
- epidermal growth factor receptor
- weight loss
- reactive oxygen species
- oxidative stress
- insulin resistance
- machine learning
- chronic pain
- pain management
- data analysis
- affordable care act